These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37698736)
21. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination. Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417 [TBL] [Abstract][Full Text] [Related]
22. The m Diao H; Tan H; Hu Y; Wang R; Cai P; Huang B; Shao X; Yan M; Yin C; Zhang Y Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259333 [TBL] [Abstract][Full Text] [Related]
23. YTH domain family protein 3 accelerates non-small cell lung cancer immune evasion through targeting CD8 Luo Y; Zeng C; Ouyang Z; Zhu W; Wang J; Chen Z; Xiao C; Wu G; Li L; Qian Y; Chen X; Liu Y; Wu H Cell Death Discov; 2024 Jul; 10(1):320. PubMed ID: 38992016 [TBL] [Abstract][Full Text] [Related]
24. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA. Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544 [TBL] [Abstract][Full Text] [Related]
25. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis. Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874 [TBL] [Abstract][Full Text] [Related]
26. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Wang QM; Lian GY; Song Y; Huang YF; Gong Y Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647 [TBL] [Abstract][Full Text] [Related]
27. Targeting m Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220 [TBL] [Abstract][Full Text] [Related]
28. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940 [TBL] [Abstract][Full Text] [Related]
29. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer. Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029 [No Abstract] [Full Text] [Related]
30. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells. Tsuruta N; Tsuchihashi K; Ohmura H; Yamaguchi K; Ito M; Ariyama H; Kusaba H; Akashi K; Baba E Biochem Biophys Res Commun; 2020 Sep; 530(1):235-239. PubMed ID: 32828292 [TBL] [Abstract][Full Text] [Related]
31. Prostate cancer cells synergistically defend against CD8 Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397 [TBL] [Abstract][Full Text] [Related]
32. m6A writer WTAP targets NRF2 to accelerate bladder cancer malignancy via m6A-dependent ferroptosis regulation. Wang K; Wang G; Li G; Zhang W; Wang Y; Lin X; Han C; Chen H; Shi L; Reheman A; Li J; Li Z; Yang X Apoptosis; 2023 Apr; 28(3-4):627-638. PubMed ID: 36719469 [TBL] [Abstract][Full Text] [Related]
33. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. Zhang Y; Zhu S; Du Y; Xu F; Sun W; Xu Z; Wang X; Qian P; Zhang Q; Feng J; Xu Y J Exp Clin Cancer Res; 2022 Feb; 41(1):66. PubMed ID: 35177112 [TBL] [Abstract][Full Text] [Related]
34. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495 [TBL] [Abstract][Full Text] [Related]
35. YTHDF1-enhanced iron metabolism depends on TFRC m Ye J; Wang Z; Chen X; Jiang X; Dong Z; Hu S; Li W; Liu Y; Liao B; Han W; Shen J; Xiao M Theranostics; 2020; 10(26):12072-12089. PubMed ID: 33204330 [No Abstract] [Full Text] [Related]
36. Methylation recognition protein YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) regulates the proliferation, migration and invasion of osteosarcoma by regulating m6A level of CCR4-NOT transcription complex subunit 7 (CNOT7). Wei K; Gao Y; Wang B; Qu YX Bioengineered; 2022 Mar; 13(3):5236-5250. PubMed ID: 35156522 [TBL] [Abstract][Full Text] [Related]
37. N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer. Wang S; Gao S; Zeng Y; Zhu L; Mo Y; Wong CC; Bao Y; Su P; Zhai J; Wang L; Soares F; Xu X; Chen H; Hezaveh K; Ci X; He A; McGaha T; O'Brien C; Rottapel R; Kang W; Wu J; Zheng G; Cai Z; Yu J; He HH Gastroenterology; 2022 Apr; 162(4):1183-1196. PubMed ID: 34968454 [TBL] [Abstract][Full Text] [Related]
39. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262 [TBL] [Abstract][Full Text] [Related]
40. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8 Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]